Odyssey Therapeutics, Inc.
ODTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 12, 2026 | UBS | $27.00(+42%) | $19.00 | TheFly | |
| Oct 8, 2026 | Raymond James | $42.00(+132%) | $18.12 | TheFly | |
| Aug 27, 2026 | H.C. Wainwright | Emily Bodnar | $44.00(+72%) | $25.62 | TheFly |
| Jun 2, 2026 | Wedbush | David Nierengarten | $30.00(+77%) | $16.96 | TheFly |
| Jun 2, 2026 | Oppenheimer | Jeff Jones | $40.00(+136%) | $16.96 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| JP Morgan | maintain | Overweight | Aug 7, 2026 |
| Oppenheimer | maintain | Outperform | Jun 18, 2026 |
Earnings History
Next report: Feb 3, 2027 · EPS est. $-1.08| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-1.10 | $-1.07 | — | — |
| Aug 4, 2026 | $-1.74 | $-1.61 | — | — |
| Jun 17, 2026 | $-6.77 | $-1.11 | — | — |
News
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor $387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028 BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage bio…
Odyssey Therapeutics NASDAQ: ODTX presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor webcast. The company said the complete induction dataset, biomarker findings and mucosal biopsy transcriptomics reinforced its selection of a 20 mg twice-daily dose for further development.
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD
Big banks kick off third-quarter earnings season tomorrow, and Wall Street analysts are already reshuffling their bets with a wave of surprise upgrades, downgrades, and fresh initiations across some of the market's most closely watched names.
Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that additional results from the OD-001 ind…
Shares of Odyssey Therapeutics, Inc. (NASDAQ: ODTX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team are scheduled to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11…
BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team will participate in the following upcoming investor conferences in September: 2026 Cantor Global Healthcare Conference …